D. E. Shaw & Co., Inc. Organon & Co. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Organon & Co. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 140,486 shares of OGN stock, worth $2.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

140,486

Holding current value

$2.07 Million

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$18.65 - $23.03 $2.62 Million - $3.24 Million	140,486 New	140,486 $2.69 Million
Q4 2023 Feb 14, 2024	BUY	$10.95 - $17.32 $2 Million - $3.16 Million	182,619 New	182,619 $2.63 Million
Q2 2023 Aug 14, 2023	BUY	$19.27 - $24.63 $253,400 - $323,884	13,150 New	13,150 $273,000
Q4 2022 Feb 14, 2023	SELL	$23.31 - $28.61 $2.23 Million - $2.73 Million	-95,593 Reduced 77.45%	27,836 $777,000
Q3 2022 Nov 14, 2022	SELL	$23.4 - $34.25 $4.33 Million - $6.33 Million	-184,848 Reduced 59.96%	123,429 $2.89 Million
Q2 2022 Aug 15, 2022	BUY	$31.66 - $38.9 $3.23 Million - $3.97 Million	102,023 Added 49.46%	308,277 $10.4 Million
Q1 2022 May 16, 2022	SELL	$30.45 - $39.36 $20 Million - $25.9 Million	-656,859 Reduced 76.1%	206,254 $7.2 Million
Q4 2021 Feb 14, 2022	BUY	$28.67 - $37.13 $2.18 Million - $2.83 Million	76,102 Added 9.67%	863,113 $26.3 Million
Q3 2021 Nov 15, 2021	SELL	$28.63 - $35.64 $10.2 Million - $12.7 Million	-357,455 Reduced 31.23%	787,011 $25.8 Million
Q2 2021 Aug 16, 2021	BUY	$28.45 - $38.0 $32.6 Million - $43.5 Million	1,144,466 New	1,144,466 $34.6 Million

Others Institutions Holding OGN

# of Institutions

791

Shares Held

193M

Call Options Held

1.71M

Put Options Held

865K

View Full List

About Organon & Co.

Ticker OGN
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 254,330,000
Market Cap $3.75B
Description
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...

More about OGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account